Kymera Therapeutics (KYMR) Competitors $43.83 -0.22 (-0.50%) (As of 09:35 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends KYMR vs. BEAM, NRIX, REPL, EDIT, ALVR, PCVX, CTLT, SRPT, QGEN, and RVMDShould you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include Beam Therapeutics (BEAM), Nurix Therapeutics (NRIX), Replimune Group (REPL), Editas Medicine (EDIT), AlloVir (ALVR), Vaxcyte (PCVX), Catalent (CTLT), Sarepta Therapeutics (SRPT), Qiagen (QGEN), and Revolution Medicines (RVMD). These companies are all part of the "medical" sector. Kymera Therapeutics vs. Beam Therapeutics Nurix Therapeutics Replimune Group Editas Medicine AlloVir Vaxcyte Catalent Sarepta Therapeutics Qiagen Revolution Medicines Kymera Therapeutics (NASDAQ:KYMR) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends. Does the MarketBeat Community prefer KYMR or BEAM? Kymera Therapeutics and Beam Therapeutics both received 51 outperform votes by MarketBeat users. However, 54.26% of users gave Beam Therapeutics an outperform vote while only 52.04% of users gave Kymera Therapeutics an outperform vote. CompanyUnderperformOutperformKymera TherapeuticsOutperform Votes5152.04% Underperform Votes4747.96% Beam TherapeuticsOutperform Votes5154.26% Underperform Votes4345.74% Does the media prefer KYMR or BEAM? In the previous week, Beam Therapeutics had 1 more articles in the media than Kymera Therapeutics. MarketBeat recorded 5 mentions for Beam Therapeutics and 4 mentions for Kymera Therapeutics. Beam Therapeutics' average media sentiment score of 0.58 beat Kymera Therapeutics' score of 0.39 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is KYMR or BEAM more profitable? Beam Therapeutics has a net margin of -41.07% compared to Kymera Therapeutics' net margin of -191.26%. Beam Therapeutics' return on equity of -16.22% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kymera Therapeutics-191.26% -24.96% -20.27% Beam Therapeutics -41.07%-16.22%-10.94% Which has better earnings & valuation, KYMR or BEAM? Beam Therapeutics has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKymera Therapeutics$87.56M32.58-$146.96M-$2.34-18.82Beam Therapeutics$377.71M5.37-$132.53M-$1.76-13.91 Do insiders and institutionals hold more shares of KYMR or BEAM? 99.7% of Beam Therapeutics shares are owned by institutional investors. 15.8% of Kymera Therapeutics shares are owned by insiders. Comparatively, 4.2% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer KYMR or BEAM? Kymera Therapeutics presently has a consensus target price of $52.13, indicating a potential upside of 18.35%. Beam Therapeutics has a consensus target price of $44.91, indicating a potential upside of 83.38%. Given Beam Therapeutics' higher possible upside, analysts clearly believe Beam Therapeutics is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kymera Therapeutics 0 Sell rating(s) 4 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.81Beam Therapeutics 0 Sell rating(s) 4 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has more risk and volatility, KYMR or BEAM? Kymera Therapeutics has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. SummaryBeam Therapeutics beats Kymera Therapeutics on 12 of the 17 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYMR vs. The Competition Export to ExcelMetricKymera TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.85B$2.93B$5.01B$8.81BDividend YieldN/A1.89%5.16%4.06%P/E Ratio-18.8245.25134.3717.77Price / Sales32.58360.241,158.6875.18Price / CashN/A160.0933.5332.53Price / Book6.193.734.674.68Net Income-$146.96M-$41.63M$119.07M$226.08M7 Day Performance-4.12%-4.73%-1.83%-1.04%1 Month Performance-5.39%-6.53%-3.62%1.04%1 Year Performance132.33%25.63%31.63%26.28% Kymera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYMRKymera Therapeutics1.4071 of 5 stars$43.83-0.5%$52.13+18.9%+110.9%$2.84B$78.59M-18.73170Analyst ForecastBEAMBeam Therapeutics2.9285 of 5 stars$24.32-0.7%$44.91+84.7%-20.4%$2.01B$377.71M-13.91461NRIXNurix Therapeutics2.7301 of 5 stars$22.53-0.5%$29.40+30.5%+247.8%$1.60B$76.99M0.00300REPLReplimune Group4.2429 of 5 stars$11.23+2.6%$16.80+49.6%+10.3%$768.36MN/A-3.68210EDITEditas Medicine4.6915 of 5 stars$2.37-1.7%$9.08+283.3%-77.8%$195.64M$78.12M-0.94230Short Interest ↓ALVRAlloVir2.6268 of 5 stars$0.570.0%N/A-65.2%$65.86MN/A0.00110Positive NewsPCVXVaxcyte3.2938 of 5 stars$85.98+0.0%$147.50+71.6%+67.2%$10.72BN/A0.00160CTLTCatalent3.0395 of 5 stars$59.00+0.2%$63.40+7.5%+47.8%$10.71B$4.38B-26.1116,900SRPTSarepta Therapeutics4.914 of 5 stars$109.71-1.0%$181.33+65.3%+33.5%$10.48B$1.24B88.691,314Analyst DowngradeGap UpQGENQiagen4.4347 of 5 stars$42.25+0.4%$50.88+20.4%+2.5%$9.64B$1.97B107.975,967Positive NewsRVMDRevolution Medicines2.7869 of 5 stars$57.07+1.1%$61.00+6.9%+162.6%$9.60B$11.58M0.00443 Related Companies and Tools Related Companies BEAM Competitors NRIX Competitors REPL Competitors EDIT Competitors ALVR Competitors PCVX Competitors CTLT Competitors SRPT Competitors QGEN Competitors RVMD Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KYMR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KYMR Stock Alerts